Biogen, Samsung Bioepis Enter New Biosimilars Transaction | Contract Pharma
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Samsung intéressé par le rachat du laboratoire Biogen pour plus de $40 milliards | Arab News FR
Biogen gains ophthalmology biosimilar candidates for Lucentis, Eylea in deal with Samsung Bioepis
Samsung Bioepis considering takeover of Biogen's unit: reports
Biogen and Samsung land FDA approval for biosimilar to blockbuster Roche drug - MedCity News
Samsung in talks to acquire Biogen, per report - The Boston Globe
Biogen and Samsung Bioepis present data for Infliximab and Adalimumab biosimilars - Hub Publishing
Samsung Biologics Buys Bioepis Stake for $2.3 Billion From Biogen - Bloomberg
Samsung s'associe à Biogen Idec
Samsung Biologics to acquire Biogen's stake in Samsung Bioepis
Samsung in Talks to Buy Alzheimer's Drug Maker Biogen for $42 Billion: Report | Technology News
Samsung BioLogics says report on Biogen deal talks untrue | Fox Business
Biogen of US might reap W2tr from Samsung Bioepis call option
Biogen Poised for Pipeline Growth, Samsung Eyes New Drug Expansion after $2.3B Joint Venture Deal
Samsung intéressé par le rachat du laboratoire Biogen | La Presse
Biosimilaires : Biogen se déleste de Samsung Bioepis
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung Bioepis ponders acquiring unit from U.S. partner Biogen
Samsung Biologics Prepares for Budding Alzheimer's Treatment Deals
Samsung Bioepis conclut un nouvel accord de commercialisation avec Biogen
Biogen shares jump higher on report of potential Samsung acquisition
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million | BioSpace
Biogen — Wikipédia
